Cargando…

The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies

Detalles Bibliográficos
Autores principales:	Yang, Chang, Lou, Ge, Jin, Wei-Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175382/ https://www.ncbi.nlm.nih.gov/pubmed/34083505 http://dx.doi.org/10.1038/s41392-021-00635-y

Ejemplares similares

Highlight: The Evolutionary Arsenal of Aphids
por: McGrath, Casey
Publicado: (2018)

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
por: You, Gihoon, et al.
Publicado: (2021)

Dissecting an adiposity locus with an arsenal of genomics
por: Lorenz, Kim, et al.
Publicado: (2018)

BET family protein degraders poised to join the senolytic arsenal
por: Guo, Zufeng, et al.
Publicado: (2020)

An anti-tumor coup: TIM3 ablation activates the immune arsenal
por: Görgülü, Kıvanç, et al.
Publicado: (2021)

ACSL4, PUFA, and ferroptosis: new arsenal in anti-tumor immunity
por: Gan, Boyi
Publicado: (2022)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Gut microbiome alters functions of mutant p53 to promote tumorigenesis
por: Lau, Harry Cheuk Hay, et al.
Publicado: (2020)

Development of Antibody‐Directed Therapies: Quo Vadis?
por: Rodrigues, Tiago, et al.
Publicado: (2018)

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
por: Wu, Jingjing, et al.
Publicado: (2015)

Pharmacologic RNA splicing modulation: a novel mechanism to enhance neoantigen-directed anti-tumor immunity and immunotherapy response
por: Elliott, Kerryn, et al.
Publicado: (2021)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)

Molecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2
por: Fagiani, Francesca, et al.
Publicado: (2020)

Bispecific immune molecule PD1-IL2v: a new therapeutic strategy for pancreatic ductal adenocarcinoma
por: Gao, Yuan, et al.
Publicado: (2023)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Single cell RNA and immune repertoire profiling of COVID-19 patients reveal novel neutralizing antibody
por: Li, Fang, et al.
Publicado: (2020)

Bispecific Antibodies and Gene Therapy
por: Nettelbeck, Dirk M.
Publicado: (2011)

Impairment of rigidity sensing caused by mutant TP53 gain of function in osteosarcoma
por: Luo, Ming, et al.
Publicado: (2023)

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
por: Kim, Jin-Ah, et al.
Publicado: (2023)

Unraveling the Dynamics of Antibody-Antigen Interaction by DNA Origami
por: Nie, Zhou
Publicado: (2020)

Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics
por: Yang, Yang, et al.
Publicado: (2022)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

NEK2, a promising target in TP53 mutant cancer
por: Cusan, Martina, et al.
Publicado: (2022)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
por: Kliebhan, Johannes, et al.
Publicado: (2022)

Opsonizing antibodies mediated SARS‐CoV‐2 entry into monocytes leads to inflammation
por: Yao, Tong, et al.
Publicado: (2022)

Bispecific antibodies: design, therapy, perspectives
por: Sedykh, Sergey E, et al.
Publicado: (2018)

Profiling and characterization of SARS-CoV-2 mutants’ infectivity and antigenicity
por: Wang, Lin, et al.
Publicado: (2020)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

On the road to epigenetic therapy
por: Walton, Emma L.
Publicado: (2016)

Mutant huntingtin in the hypothalamus causes metabolic dysfunction
Publicado: (2011)

SARS-CoV-2 variant Omicron: currently the most complete “escapee” from neutralization by antibodies and vaccines
por: Li, Maochen, et al.
Publicado: (2022)

Who Has Therapy-Related AML?
por: Gale, Robert Peter, et al.
Publicado: (2017)

Towards gene therapy for IPEX syndrome
por: Borna, Simon, et al.
Publicado: (2022)

Ascorbate Inhibits Proliferation and Promotes Myeloid Differentiation in TP53-Mutant Leukemia
por: Smith-Díaz, Carlos C., et al.
Publicado: (2021)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion
por: Guo, Alvin Kunyao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ar34k7imkhe5690mevidu8srr7